| Name | Title | Contact Details |
|---|
iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.
Suncoast Perfusion Services is a Fort Myers, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Molecular Toxicology is a Boone, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ology Bioservices is a private, American biopharmaceutical company headquartered in Alachua, Florida.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.